Clinical trials: Cirrhosis Early
Cirrhosis, Hepotacellular Carcinoma
The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients
Hepatocellular carcinoma (HCC) is a globally prevalent malignancy. In its characteristic "chronic hepatitis-liver cirrhosis-HCC" progression trilogy, patients with cirrhosis demonstrate a 5-year HCC incidence rate of 3%-5%, yet…
- Trial name
- AKR1B10 (NCT07147335)
- Testing
- serum AKR1B10 levels
- Where
- China
- Volunteers
- 800 people
- Sponsor
- The First Affiliated Hospital of University of South China
Lysosomal Acid Lipase Deficiency, Wolman Disease
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
This was an open-label, repeat-dose, intra-participant dose-escalation study of SBC-102 (sebelipase alfa) in children with growth failure due to lysosomal acid lipase (LAL) Deficiency.
- Trial name
- NCT01371825
- Testing
- Sebelipase alfa (SBC-102)
- Where
- 7 sites in United States, Egypt and 3 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Liver Fibrosis
Three-Dimensional T1rho Using Spiral Fast Spin Echo
Liver fibrosis is the main feature in early chronic liver diseases. If identified early, liver fibrosis is reversible. The current gold standard for diagnosing liver fibrosis is invasive liver biopsy.
- Trial name
- NCT05154656
- Where
- Hong Kong
- Volunteers
- healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Upper Digestive Bleeding, Cirrhosis
Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding
Upper digestive bleeding. Upper gastrointestinal haemorrhage is a common cause of decompensated cirrhosis and is associated with a high mortality rate among cirrhotic patients.
- Trial name
- EXARHOSE (NCT03023189)
- Testing
- Tranexamic acid
- Where
- 3 sites in France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma, Liver Cancer
FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer.
Intro: Hepatocellular carcinoma (HCC) is the 6th leading cause of cancer worldwide. In France, more than 10,000 new cases are identified each year.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Cirrhosis, Chronic Liver Disease
- Trial name
- FASTRAK (NCT05095714)
- Testing
- Liver ultrasound and fast-MRI, Liver ultrasound
- Where
- France
- Volunteers
- 944 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cystic Fibrosis, Liver Fibroses
The Use of Novel Diagnostic Tools to Increase Detection of Early Fibrosis in Cystic Fibrosis Related Liver Disease to Improve Clinical Management
Cystic Fibrosis (CF) is a genetic condition which affects 1 in 2500 newborn infants and is the commonest genetic condition in the UK. 1 in 25 of the white population carry the mutation.
- Conditions
- Cystic Fibrosis, Liver Fibroses, Cystic Fibrosis Liver Disease
- Trial name
- NCT04277819
- Where
- United Kingdom
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Manchester University NHS Foundation Trust
Alcoholic Hepatitis, Alcoholic Cirrhosis
Validation of the Procedure of Early Liver Transplantation in Alcoholic Hepatitis Resisting to Medical Treatment
The purpose of this study is to validate a strategy of identification of patients for early liver transplantation in severe alcoholic hepatitis. In this setting, short-term survival is very low (approx.
- Trial name
- QuickTrans (NCT01756794)
- Testing
- Liver transplantation
- Where
- 32 sites in Belgium, France
- Volunteers
- 284 people
- Sponsor
- University Hospital, Lille
Early Cirrhosis
Clinical Food Study to Evaluate the Effect of KB174 on the Gut Microbiome in Subjects With Well-compensated Cirrhosis
This randomized, double-blind, controlled, clinical food study aims to explore KB174, a novel mixture of oligosaccharides, and maltodextrin, an easily digestible polysaccharide, on gut microbiome structure and function in…
- Trial name
- NCT03855956
- Testing
- KB174, Maltodextrin
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kaleido Biosciences
Primary Biliary Cholangitis, Intrahepatic Bile Duct Cancer
Patients With Primary Biliary Cholangitis
Primary biliary cholangitis (PBC) is a chronic autoimmune disease characterized by progressive destruction of the small intrahepatic bile ducts, leading to cholestasis and potential progression to cirrhosis.
- Conditions
- Primary Biliary Cholangitis, Intrahepatic Bile Duct Cancer, Cancer Liver
- Trial name
- BILIFLEX (NCT07573514)
- Testing
- Reflex AMA and ANA testing
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Primary Biliary Cholangitis, Cardiovascular Abnormalities
Early Identification of Myocardial Impairment in PBC
Primary biliary cholangitis (PBC) is a chronic inflammatory liver disease leading to cirrhosis. Researches reported patients with PBC may involve abnormalities on skeleton, thyroid and exocrine glands.
- Trial name
- EARLY-MYO-PBC (NCT03545672)
- Testing
- CMR examination
- Where
- China
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Cirrhosis
Effects of Home Based Exercise Therapy in Early Cirrhosis
Individuals with Cirrhosis have been shown to have a low aerobic capacity. While supervised exercise training has been shown to be an effective intervention to remedy this, there is currently no data on home based exercise…
- Trial name
- NCT02267421
- Testing
- Home based Aerobic exercise training
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Alberta
Cirrhosis, Hepatocellular Carcinoma
Project OASIS: Optimizing Approaches to Select Implementation Strategies
Barriers that prevent healthcare methods supported by science from being adopted in the real world have led to low-quality, inequitable medical care.
- Trial name
- OASIS (NCT06061328)
- Testing
- OASIS DA training, Current DA Tool training
- Where
- United States
- Volunteers
- 8,020 people
- Sponsor
- VA Office of Research and Development
Cirrhosis, Diabetes Mellitus
Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments
The purpose of this study is to assess the superiority of esmolol echocardiography over conventional echocardiography in the diagnosis of subclinical myocardial involvement associated with diabetes mellitus 2, cirrhosis and…
- Conditions
- Cirrhosis, Diabetes Mellitus, Oncologic Disorders
- Trial name
- CIBERbBECHO (NCT05769868)
- Testing
- Esmolol Injection [Brevibloc]
- Where
- 6 sites in Spain
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Hepatitis C
Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
The purpose of this early access program is to provide telaprevir to patients with a specific type of hepatitis C viral infection (termed 'genotype 1') who are expected to benefit from telaprevir-based therapy but who reside in…
- Trial name
- NCT01508286
- Testing
- Telaprevir + peginterferon alfa + ribavirin, peginterferon alfa + ribavirin
- Where
- 128 sites in Australia, Austria and 13 more
- Sponsor
- Janssen-Cilag International NV